Literature DB >> 22316135

Inflammasome and caspase-1 inhibition caused by Bcl-2 and Bcl-XL may influence cytokine responses of lipopolysaccharide-stimulated peripheral blood mononuclear cells from septic patients.

Zhao-Jun Liu, Jia-Lin Liu, Hong-Ping Qu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22316135      PMCID: PMC3396247          DOI: 10.1186/cc11156

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

In recent issues of Critical Care, Wu and colleagues [1] and Giamarellos-Bourboulis and colleagues [2] observed that cytokine responses in different concentrations of lipo polysaccharide (LPS) (1 and 10 pg/μL, respectively) stimulated peripheral blood mononuclear cells (PBMCs) of septic patients and healthy controls. Wu and colleagues found that interleukin-1beta (IL-1β) production of PBMCs from patients with sepsis was significantly higher than that from controls, whereas Giamarellos-Bourboulis and colleagues found the opposite result. In light of previous research, we would like to offer some remarks. LPS can lead to the activation of nuclear factor-kappa-B (NF-κB) and the subsequent generation of pro-IL-1β [3], which is readily processe d into IL-1β by inflammasome-activated caspase-1 [4]. NF-κB also induces B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-XL), both of which could suppress the activation of caspase-1 by inhibiting NLRP1 (pyrin-containing nonobese diabetic-like receptor 1) and thus suppress the cleavage of pro-IL-1β [5]. When PBMCs were stimulated with low concentrations of LPS, the expression of pro-IL-1β could be predominant and functions of inflammasomes and caspase-1 were still reserved and thus IL-1β production was increased. When PBMCs were stimulated with high concentrations of LPS, the expression of Bcl-XL/Bcl-2 could greatly increase and lead to significant inhibition of caspase-1 and thus the production of IL-1β was decreased, although the expression of pro-IL-1β may not have been influenced significantly [2]. That may be the reason why the results of the two sets of authors were conflicting. Since Bcl-2/Bcl-XL could be differently produced according to various concentrations of LPS, inhibiting Bcl-2/Bcl-XL with reagents like ABT-737 in order to make sure that inflammasome and caspase-1 are not suppressed in vitro would be necessary when trying to use LPS stimulation to assess the status of PBMCs from patients with sepsis.

Abbreviations

Bcl-2: B-cell lymphoma 2; Bcl-XL: B-cell lymphoma-extra large; IL-1β: interleukin-1beta; LPS: lipopolysaccharide; NF-κB: nuclear factor-kappa-B; PBMC: peripheral blood mononuclear cell.

Competing interests

The authors declare that they have no competing interests.
  5 in total

Review 1.  The inflammasomes.

Authors:  Kate Schroder; Jurg Tschopp
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  Harmful molecular mechanisms in sepsis.

Authors:  Daniel Rittirsch; Michael A Flierl; Peter A Ward
Journal:  Nat Rev Immunol       Date:  2008-10       Impact factor: 53.106

3.  Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1.

Authors:  Jean-Marie Bruey; Nathalie Bruey-Sedano; Frederic Luciano; Dayong Zhai; Ruchi Balpai; Chunyan Xu; Christina L Kress; Beatrice Bailly-Maitre; Xiaoqing Li; Andrei Osterman; Shu-ichi Matsuzawa; Alexey V Terskikh; Benjamin Faustin; John C Reed
Journal:  Cell       Date:  2007-04-06       Impact factor: 41.582

4.  Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia.

Authors:  Evangelos J Giamarellos-Bourboulis; Frank L van de Veerdonk; Maria Mouktaroudi; Maria Raftogiannis; Anastasia Antonopoulou; Leo A B Joosten; Peter Pickkers; Athina Savva; Marianna Georgitsi; Jos W M van der Meer; Mihai G Netea
Journal:  Crit Care       Date:  2011-01-18       Impact factor: 9.097

5.  Serial increase of IL-12 response and human leukocyte antigen-DR expression in severe sepsis survivors.

Authors:  Huang-Pin Wu; Chi-Chung Shih; Chun-Yao Lin; Chung-Ching Hua; Duen-Yau Chuang
Journal:  Crit Care       Date:  2011-09-22       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.